89 related articles for article (PubMed ID: 8566106)
1. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum.
Hill MP; Brotchie JM
Eur J Pharmacol; 1995 Jul; 281(1):R1-R2. PubMed ID: 8566106
[TBL] [Abstract][Full Text] [Related]
2. Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum.
Hill MP; Brotchie JM
Br J Pharmacol; 1999 May; 127(1):275-83. PubMed ID: 10369483
[TBL] [Abstract][Full Text] [Related]
3. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
Maneuf YP; Mitchell IJ; Crossman AR; Woodruff GN; Brotchie JM
Brain Res; 1995 Jun; 683(1):102-8. PubMed ID: 7552334
[TBL] [Abstract][Full Text] [Related]
4. Presynaptic kappa-opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes.
Rawls SM; McGinty JF; Terrian DM
J Neurochem; 1999 Sep; 73(3):1058-65. PubMed ID: 10461895
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes.
East SJ; Hill MP; Brotchie JM
Eur J Pharmacol; 1995 Apr; 277(1):117-21. PubMed ID: 7635167
[TBL] [Abstract][Full Text] [Related]
6. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
Hughes NR; McKnight AT; Woodruff GN; Hill MP; Crossman AR; Brotchie JM
Mov Disord; 1998 Mar; 13(2):228-33. PubMed ID: 9539334
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibitory action of enadoline (CI977) on release of amino acids in the rat hippocampus.
Millan MH; Chapman AG; Meldrum BS
Eur J Pharmacol; 1995 Jun; 279(1):75-81. PubMed ID: 7556386
[TBL] [Abstract][Full Text] [Related]
8. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
Hill MP; Brotchie JM
Br J Pharmacol; 1999 Dec; 128(7):1577-85. PubMed ID: 10602339
[TBL] [Abstract][Full Text] [Related]
9. Kappa receptor activation attenuates L-trans-pyrrolidine-2,4-dicarboxylic acid-evoked glutamate levels in the striatum.
Rawls SM; McGinty JF
J Neurochem; 1998 Feb; 70(2):626-34. PubMed ID: 9453556
[TBL] [Abstract][Full Text] [Related]
10. The relationship between glutamate release and cerebral blood flow after focal cerebral ischaemia in the cat: effect of pretreatment with enadoline (a kappa receptor agonist).
MacKay KB; Patel TR; Galbraith SL; Woodruff GN; McCulloch J
Brain Res; 1996 Mar; 712(2):329-34. PubMed ID: 8814909
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the antinociceptive actions of the kappa-opioid agonist enadoline (CI-977) in neonatal and adult rats: comparison to kappa-opioid receptor mRNA ontogeny.
McLaughlin CR; Tao Q; Abood ME
Drug Alcohol Depend; 1995 Jun; 38(3):261-9. PubMed ID: 7555627
[TBL] [Abstract][Full Text] [Related]
12. Nalfurafine, the kappa opioid agonist, inhibits icilin-induced wet-dog shakes in rats and antagonizes glutamate release in the dorsal striatum.
Werkheiser JL; Rawls SM; Cowan A
Neuropharmacology; 2007 Mar; 52(3):925-30. PubMed ID: 17150231
[TBL] [Abstract][Full Text] [Related]
13. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists.
Carey GJ; Bergman J
J Pharmacol Exp Ther; 2001 Apr; 297(1):215-23. PubMed ID: 11259547
[TBL] [Abstract][Full Text] [Related]
14. Selective depression of dorsal root-evoked high threshold synaptic excitation by the selective kappa opioid receptor agonist enadoline in the neonatal rat hemisected spinal cord in vitro.
Faber ES; Chambers JP; Evans RH
Neuropharmacology; 1998 Jun; 37(6):745-50. PubMed ID: 9707288
[TBL] [Abstract][Full Text] [Related]
15. Modulation of adenosine concentration by opioid receptor agonists in rat striatum.
Halimi G; Devaux C; Clot-Faybesse O; Sampol J; Legof L; Rochat H; Guieu R
Eur J Pharmacol; 2000 Jun; 398(2):217-24. PubMed ID: 10854833
[TBL] [Abstract][Full Text] [Related]
16. The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum.
Gray AM; Rawls SM; Shippenberg TS; McGinty JF
J Neurochem; 1999 Sep; 73(3):1066-74. PubMed ID: 10461896
[TBL] [Abstract][Full Text] [Related]
17. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs.
Werling LL; Frattali A; Portoghese PS; Takemori AE; Cox BM
J Pharmacol Exp Ther; 1988 Jul; 246(1):282-6. PubMed ID: 2839666
[TBL] [Abstract][Full Text] [Related]
18. Histamine H3 receptor activation inhibits glutamate release from rat striatal synaptosomes.
Molina-Hernández A; Nuñez A; Sierra JJ; Arias-Montaño JA
Neuropharmacology; 2001 Dec; 41(8):928-34. PubMed ID: 11747897
[TBL] [Abstract][Full Text] [Related]
19. alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release.
Kaiser S; Wonnacott S
Mol Pharmacol; 2000 Aug; 58(2):312-8. PubMed ID: 10908298
[TBL] [Abstract][Full Text] [Related]
20. The neuroprotective kappa-opioid CI-977 alters glutamate-induced calcium signaling in vitro.
DeCoster MA; Conover JR; Hunter JC; Tortella FC
Neuroreport; 1994 Nov; 5(17):2305-10. PubMed ID: 7881051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
